

P1 cont.
administering to said human an anti-cancer effective amount of a compound selected from the group consisting of gossypol, gossypolone, [anti-cancer effective metabolites thereof,] or physiologically acceptable salts thereof, and a pharmaceutically acceptable carrier.

P2.
Claim ~~3~~². (Amended) The method of claim 1 [or 2], wherein said cancer is adrenal, ovarian, thyroid, testicular, pituitary, prostate, or breast cancer.

P3
Claim 13. (Amended) A method for treating a cancer in a human, wherein the cancer is susceptible to treatment with gossypol or a pharmaceutically acceptable salt thereof, which comprises:

administering to said human an anti-cancer effective amount of gossypol, [an anti-cancer effective metabolite thereof,] or a physiologically acceptable salt thereof, and a pharmaceutical carrier.

REMARKS

Upon entry of the present Amendment, claims 1, 3-4 and 13-15 will remain pending in the above-identified application and stand ready for further action on the merits.

The above amendments to the claims do not incorporate new matter into the application as originally filed. For example, claims 1 and 13, have amended to more precisely recite that the